Shift Bioscience
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Moneta Building 280 Babraham Research Ca...Website
www.shiftbioscience.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Shift Bioscience
Shift Biosciences is a Cambridge, UK-based biotech company using generative AI models for aging processes. Led by CEO Dr Daniel Ives, Shift Bioscience is building a cell simulation platform that combines generative AI with its biological aging clock, to predict which sets of genes are most likely to safely rejuvenate specific cells and then test, improve and validate these predictions.Explore more
Shift Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Shift Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Shift Bioscience
Earning: See what the market has to say on Shift Bioscience recently announced quarterly report
Product Launch: Get notified when Shift Bioscience launches new products
Click to see if Shift Bioscience had a recent Job posting/layoffs
Shift Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Shift Bioscience is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Shift Bioscience has new funding data
Check if Shift Bioscience has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Shift Bioscience
Find 3 more new buyers
Compare Similar Companies to Shift Bioscience
Compare insights from companies similar to Shift Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Shift Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Shift Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Shift Bioscience.
Shift Bioscience financials insights
Gather financial insights about Shift Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Angel/Seed
$18M
Angel/Seed
$16M
Shift Bioscience Tech Stack
A closer look at the technologies used by Shift Bioscience
See more technologies
Most Recent Scoops
Event
Person-Based
Daniel Ives, Chief Executive Officer & Founder, appeared on a podcast called "FT Tech Tonic" on 12/10/2025. Topics discussed include Longevity, Gene Therapy, Ethics.
Events, Podcast
Person-Based
Person-Based
Person-Based
Funding
Funding
Shift Bioscience News & Media
Shift Bioscience Announces Key Appointments to Advance Rejuvenation Therapeutics Pipeline
CAMBRIDGE, England--(BUSINESS WIRE)--Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the appointments of Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, Ph.D., as Non-Executive Director. In these roles, Jill and Laurence will guide Shift in building a robust product translation and business development strategy respectively, enabling the Company to capitalize on early momentum and progress its pipeline of novel rShift Bioscience Establishes North American Facilities to Expand Capabilities of AI-Powered Virtual Cell Technology
CAMBRIDGE, England & TORONTO--(BUSINESS WIRE)--Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the establishment of a new North American team and facilities to advance development of the Company’s platform for discovery of rejuvenation gene targets. Based in Toronto, Canada, the team will be led by Lucas Camillo, Head of Machine Learning, with Professor Bo Wang appointed as Senior Advisor. By expanding into this AI hub, theShift Bioscience: $16 Million (Seed) Raised To Use GenAI For Reversing Aging Processes
Shift Bioscience—a biotech company using generative AI models to understand how activation of different genes can reverse the aging process—announced it raised $16 million in seed funding. This round was led by BGF, with existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner participating.Shift Bioscience raises £12.5M to advance AI-driven ageing research
Shift Bioscience has raised £12.5 million in Seed funding. The new investment brings the total raised by the company to £14 million.The biotech company uses generative AI models to understand how the...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Shift Bioscience
Sign Up For FreeTo access detailed company insights
Shift Biosciences is a Cambridge, UK-based biotech company using generative AI models for aging processes. Led by CEO Dr Daniel Ives, Shift Bioscience is building a cell simulation platform that combines generative AI with its biological aging clock, to predict which sets of genes are most likely to safely rejuvenate specific cells and then test, i... Read More
